Adaptive Historical Financial Ratios
| ADPT Stock | USD 2.51 0.11 4.58% |
Adaptive Biotechnologies is presently reporting on over 114 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, PTB Ratio of 2.41 or Days Sales Outstanding of 43.4 will help investors to properly organize and evaluate Adaptive Biotechnologies financial condition quickly.
Adaptive |
About Adaptive Financial Ratios Analysis
Adaptive BiotechnologiesFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Adaptive Biotechnologies investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Adaptive financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Adaptive Biotechnologies history.
Adaptive Biotechnologies Financial Ratios Chart
Adaptive Biotechnologies Corp financial ratios usually calculated using numerical values taken directly from Adaptive Biotechnologies financial statements such as income statements or balance sheets. They help investors to obtain meaningful information about Adaptive Biotechnologies. Most financial ratios help to conduct quantitative analysis to assess vital information about the company's valuation as well as profitability and liquidity indicators such as leverage, growth, profit margins, and different types of rates of return.
At this time, Adaptive Biotechnologies' Days Payables Outstanding is comparatively stable compared to the past year. Income Quality is likely to gain to 0.73 in 2024, despite the fact that Free Cash Flow Yield is likely to grow to (0.22). Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Adaptive Biotechnologies stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Adaptive Biotechnologies sales, a figure that is much harder to manipulate than other Adaptive Biotechnologies Corp multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company’s stock price to its revenues, calculated by dividing the company’s market cap by its total sales or revenue over a 12-month period.Invested Capital
Invested capital represents the total cash investment that shareholders and debt holders have contributed to Adaptive Biotechnologies Corp. There are two different methods for calculating Adaptive Biotechnologies invested capital: operating approach and financing approach. Understanding Adaptive Biotechnologies invested capital allows investors to calculate measures of performance such as return on invested capital or return on capital employed.Ev To Sales
The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.Most ratios from Adaptive Biotechnologies' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Adaptive Biotechnologies current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adaptive Biotechnologies Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. At this time, Adaptive Biotechnologies' Days Payables Outstanding is comparatively stable compared to the past year. Income Quality is likely to gain to 0.73 in 2024, despite the fact that Free Cash Flow Yield is likely to grow to (0.22).
| 2021 | 2022 | 2023 | 2024 (projected) | Payables Turnover | 14.91 | 7.16 | 12.67 | 7.5 | Days Of Inventory On Hand | 142.61 | 91.1 | 53.93 | 51.23 |
Adaptive Biotechnologies fundamentals Correlations
Click cells to compare fundamentals
Adaptive Biotechnologies Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Adaptive Biotechnologies fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Price To Sales Ratio | 24.33 | 78.86 | 25.52 | 5.88 | 4.15 | 3.95 | |
| Ptb Ratio | 3.62 | 10.44 | 6.52 | 2.35 | 2.29 | 2.41 | |
| Days Sales Outstanding | 54.39 | 37.27 | 41.17 | 78.9 | 83.53 | 43.4 | |
| Book Value Per Share | 8.26 | 5.66 | 4.3 | 3.26 | 2.14 | 2.18 | |
| Free Cash Flow Yield | 0.0938 | (0.0217) | (0.0646) | (0.18) | (0.24) | (0.22) | |
| Operating Cash Flow Per Share | 2.97 | (1.14) | (1.37) | (1.29) | (1.08) | (1.03) | |
| Stock Based Compensation To Revenue | 0.2 | 0.15 | 0.25 | 0.28 | 0.3 | 0.37 | |
| Capex To Depreciation | (1.44) | (2.22) | (4.43) | (0.78) | (0.48) | (0.51) | |
| Pb Ratio | 3.62 | 10.44 | 6.52 | 2.35 | 2.29 | 2.41 | |
| Ev To Sales | 23.62 | 78.71 | 25.34 | 5.97 | 5.12 | 4.86 | |
| Free Cash Flow Per Share | 2.81 | (1.28) | (1.81) | (1.41) | (1.16) | (1.1) | |
| Roic | (0.11) | (0.17) | (0.29) | (0.25) | (0.45) | (0.43) | |
| Inventory Turnover | 2.46 | 1.6 | 2.56 | 4.01 | 6.77 | 7.11 | |
| Net Income Per Share | (0.85) | (1.06) | (1.46) | (1.0) | (1.56) | (1.64) | |
| Days Of Inventory On Hand | 148.61 | 227.83 | 142.61 | 91.1 | 53.93 | 51.23 | |
| Payables Turnover | 5.0 | 6.96 | 14.91 | 7.16 | 12.67 | 7.5 | |
| Sales General And Administrative To Revenue | 0.37 | 0.36 | 0.5 | 0.48 | 0.49 | 0.35 | |
| Capex To Revenue | (0.13) | (0.19) | (0.4) | (0.0882) | (0.0628) | (0.066) | |
| Cash Per Share | 8.34 | 5.25 | 2.52 | 3.5 | 2.4 | 3.99 | |
| Pocfratio | 10.07 | (51.84) | (20.43) | (5.92) | (4.53) | (4.75) | |
| Capex To Operating Cash Flow | (0.0545) | 0.13 | 0.32 | 0.0889 | 0.0684 | 0.096 | |
| Pfcf Ratio | 10.66 | (46.05) | (15.48) | (5.44) | (4.24) | (4.45) | |
| Days Payables Outstanding | 72.97 | 52.44 | 24.48 | 50.95 | 28.81 | 48.5 | |
| Income Quality | 0.69 | (2.99) | 1.02 | 0.93 | 0.92 | 0.73 | |
| Roe | (0.1) | (0.19) | (0.34) | (0.31) | (0.73) | (0.69) | |
| Ev To Operating Cash Flow | 9.78 | (51.73) | (20.29) | (6.02) | (5.58) | (5.86) | |
| Pe Ratio | (35.18) | (55.56) | (19.15) | (7.64) | (3.14) | (3.3) | |
| Return On Tangible Assets | (0.23) | (0.0753) | (0.14) | (0.26) | (0.42) | (0.44) | |
| Ev To Free Cash Flow | 10.35 | (45.96) | (15.37) | (5.53) | (5.22) | (5.48) | |
| Earnings Yield | (0.0284) | (0.018) | (0.0522) | (0.13) | (0.32) | (0.3) | |
| Intangibles To Total Assets | 0.4 | 0.14 | 0.12 | 0.15 | 0.19 | 0.23 | |
| Net Debt To E B I T D A | 0.78 | 0.1 | 0.13 | (0.0924) | (0.92) | (0.87) | |
| Current Ratio | 7.82 | 6.91 | 3.54 | 5.12 | 4.66 | 7.19 | |
| Tangible Book Value Per Share | 6.36 | 4.68 | 3.4 | 2.37 | 1.28 | 1.26 | |
| Receivables Turnover | 6.71 | 9.79 | 8.87 | 4.63 | 4.37 | 8.31 | |
| Graham Number | 12.57 | 11.65 | 11.91 | 8.56 | 8.66 | 7.16 | |
| Shareholders Equity Per Share | 8.26 | 5.66 | 4.3 | 3.26 | 2.14 | 2.18 |
Adaptive Biotechnologies Investors Sentiment
The influence of Adaptive Biotechnologies' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Adaptive. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Adaptive Biotechnologies' public news can be used to forecast risks associated with an investment in Adaptive. The trend in average sentiment can be used to explain how an investor holding Adaptive can time the market purely based on public headlines and social activities around Adaptive Biotechnologies Corp. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Adaptive Biotechnologies' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Adaptive Biotechnologies' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Adaptive Biotechnologies' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Adaptive Biotechnologies.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Adaptive Biotechnologies in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Adaptive Biotechnologies' short interest history, or implied volatility extrapolated from Adaptive Biotechnologies options trading.
Pair Trading with Adaptive Biotechnologies
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Adaptive Biotechnologies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Adaptive Biotechnologies will appreciate offsetting losses from the drop in the long position's value.Moving against Adaptive Stock
| 0.65 | OPT | Opthea | PairCorr |
| 0.52 | ELYM | Eliem Therapeutics | PairCorr |
| 0.47 | A | Agilent Technologies Earnings Call This Week | PairCorr |
| 0.43 | LLY | Eli Lilly Earnings Call This Week | PairCorr |
| 0.42 | MTD | Mettler Toledo Inter Financial Report 2nd of May 2024 | PairCorr |
The ability to find closely correlated positions to Adaptive Biotechnologies could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Adaptive Biotechnologies when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Adaptive Biotechnologies - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Adaptive Biotechnologies Corp to buy it.
The correlation of Adaptive Biotechnologies is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Adaptive Biotechnologies moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Adaptive Biotechnologies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Adaptive Biotechnologies can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adaptive Biotechnologies Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Complementary Tools for Adaptive Stock analysis
When running Adaptive Biotechnologies' price analysis, check to measure Adaptive Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptive Biotechnologies is operating at the current time. Most of Adaptive Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adaptive Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptive Biotechnologies' price. Additionally, you may evaluate how the addition of Adaptive Biotechnologies to your portfolios can decrease your overall portfolio volatility.
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |
Is Adaptive Biotechnologies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adaptive Biotechnologies. If investors know Adaptive will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adaptive Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.56) | Revenue Per Share 1.179 | Quarterly Revenue Growth (0.17) | Return On Assets (0.17) | Return On Equity (0.58) |
The market value of Adaptive Biotechnologies is measured differently than its book value, which is the value of Adaptive that is recorded on the company's balance sheet. Investors also form their own opinion of Adaptive Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Adaptive Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adaptive Biotechnologies' market value can be influenced by many factors that don't directly affect Adaptive Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adaptive Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adaptive Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adaptive Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.